Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Adam on +441494 818 010 or adam@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
adam@zenopa.com
+441494 818 010

Testimonials
The team at Zenopa helped me to find my first job, they took the time to understand the type of job I was looking for.
Charlotte , 2013

Novartis receives preliminary NICE recommendation for Gilenya

20 March 2012 00:00 in Pharmaceutical Company Product News


Novartis' multiple sclerosis therapy Gilenya (fingolimod) has won a provisional recommendation from the National Institute for Health and Clinical Excellence (NICE).

Final draft guidance from the UK regulator has outlined plans to endorse the therapy as a means of reducing relapse rates among patients with highly active relapsing-remitting multiple sclerosis.

It is the first pill-based medicine to demonstrate this capability, with the new recommendation representing an alteration of NICE's previous stance, thanks to the provision of relevant new information and analysis by Novartis.

If approved, Gilenya would be specifically recommended for patients affected by unchanged or increased relapse rates or ongoing severe relapses compared to the previous year, despite taking drugs such as beta interferons.

Professor Carole Longson, director of the health technology evaluation centre at NICE, said: "The analyses show that ... treatment with fingolimod will be a cost-effective option for the NHS in this group of people with multiple sclerosis, if Novartis provides the drug at a discounted price."

Last month, the company received European approval for its anticancer agent Glivec in a new specification as a treatment for post-surgical adult patients with KIT-positive gastrointestinal stromal tumours.ADNFCR-8000103-ID-801321615-ADNFCR

Other news stories from 20/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd